Lotus Pharmaceutical Co (TPE:1795) Beneish M-Score: -2.14 (As of Aug. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1795 Lotus Pharmaceutical Co Ltd TPE:1795
78 GF Score
Price NT$193.50
GF Value NT$389.59
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Lotus Pharmaceutical Co Beneish M-Score?

Lotus Pharmaceutical Co TPE:1795 +2.93% 78 Beneish M-Score is -2.14 as of Aug. 11, 2026. GuruFocus rates TPE:1795 with a GF Score™ of 78/100 and a GF Value™ of NT$389.59 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 913 Drug Manufacturers companies, Lotus Pharmaceutical Co ranks worse than 72.84% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.14 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Lotus Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

TPE:1795' s Beneish M-Score Range Over the Past 10 Years
Min: -3.06   Med: -2.39   Max: -1.77
Current: -2.14

During the past 13 years, the highest Beneish M-Score of Lotus Pharmaceutical Co was -1.77. The lowest was -3.06. And the median was -2.39.


Lotus Pharmaceutical Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Lotus Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lotus Pharmaceutical Co Beneish M-Score Chart

Lotus Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.02 -2.32 -1.85 -2.54 -2.46

Lotus Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.61 -2.83 -3.01 -2.46 -2.14

TPE:1795 vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lotus Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lotus Pharmaceutical Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lotus Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Lotus Pharmaceutical Co's Beneish M-Score falls into.


TPE:1795
78GF Score
Lotus Pharmaceutical Co Ltd TPE:1795
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lotus Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Lotus Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9919+0.528 * 1.1018+0.404 * 1.4036+0.892 * 1.2777+0.115 * 1.381
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1246+4.679 * -0.008149-0.327 * 1.3186
=-2.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was NT$8,858 Mil.
Revenue was 8644.409 + 6261.966 + 4770.699 + 4747.025 = NT$24,424 Mil.
Gross Profit was 4385.622 + 3463.727 + 2734.497 + 2793.143 = NT$13,377 Mil.
Total Current Assets was NT$25,896 Mil.
Total Assets was NT$107,534 Mil.
Property, Plant and Equipment(Net PPE) was NT$7,679 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$1,816 Mil.
Selling, General, & Admin. Expense(SGA) was NT$6,114 Mil.
Total Current Liabilities was NT$16,238 Mil.
Long-Term Debt & Capital Lease Obligation was NT$44,463 Mil.
Net Income was 567.201 + 1121.65 + 1434.709 + 728.263 = NT$3,852 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0 Mil.
Cash Flow from Operations was -24.955 + 1349.17 + 2472.509 + 931.407 = NT$4,728 Mil.
Total Receivables was NT$6,989 Mil.
Revenue was 4729.784 + 4408.951 + 5234.204 + 4742.928 = NT$19,116 Mil.
Gross Profit was 2915.302 + 2426.09 + 3315.5 + 2878.991 = NT$11,536 Mil.
Total Current Assets was NT$17,069 Mil.
Total Assets was NT$40,672 Mil.
Property, Plant and Equipment(Net PPE) was NT$3,673 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$1,318 Mil.
Selling, General, & Admin. Expense(SGA) was NT$4,255 Mil.
Total Current Liabilities was NT$8,834 Mil.
Long-Term Debt & Capital Lease Obligation was NT$8,578 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(8857.931 / 24424.099) / (6989.096 / 19115.867)
=0.362672 / 0.365618
=0.9919

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(11535.883 / 19115.867) / (13376.989 / 24424.099)
=0.603472 / 0.547696
=1.1018

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (25895.685 + 7678.55) / 107533.585) / (1 - (17068.557 + 3673.2) / 40671.506)
=0.687779 / 0.490017
=1.4036

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=24424.099 / 19115.867
=1.2777

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1318.224 / (1318.224 + 3673.2)) / (1815.686 / (1815.686 + 7678.55))
=0.264098 / 0.191241
=1.381

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(6114.299 / 24424.099) / (4255.289 / 19115.867)
=0.250339 / 0.222605
=1.1246

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((44463.226 + 16238.147) / 107533.585) / ((8577.646 + 8833.902) / 40671.506)
=0.564488 / 0.428102
=1.3186

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(3851.823 - 0 - 4728.131) / 107533.585
=-0.008149

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Lotus Pharmaceutical Co has a M-score of -2.14 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.14 mean?
Lotus Pharmaceutical Co (TPE:1795) has a Beneish M-Score of -2.14 as of Aug. 11, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Lotus Pharmaceutical Co and its competitors. According to the industry distribution chart, Lotus Pharmaceutical Co ranks #665 out of 913 companies in the Drug Manufacturers industry, placing it in the top 72.8%.
Is Lotus Pharmaceutical Co's Beneish M-Score too high?
Lotus Pharmaceutical Co's current Beneish M-Score is -2.14. Based on the distribution chart, Lotus Pharmaceutical Co ranks #665 out of 913 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Lotus Pharmaceutical Co has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lotus Pharmaceutical Co's Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Lotus Pharmaceutical Co ranks #665 out of 913 companies for Beneish M-Score. This places Lotus Pharmaceutical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Lotus Pharmaceutical Co and its competitors. Lotus Pharmaceutical Co's current Beneish M-Score is -2.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lotus Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co (TPE:1795) is currently considered Possible Value Trap. The stock's GF Value™ is NT$389.59, compared to a current price of NT$193.50 — trading 50.3% below its estimated fair value. The current Beneish M-Score is -2.14. Lotus Pharmaceutical Co's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Lotus Pharmaceutical Co (TPE:1795), the current Beneish M-Score is -2.14 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lotus Pharmaceutical Co (TPE:1795) Overvalued in 2026?

Based on GuruFocus' analysis, Lotus Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$193.50 is trading 50.3% below its estimated GF Value™ of NT$389.59. GuruFocus considers Lotus Pharmaceutical Co to be Possible Value Trap.

Key valuation signals for TPE:1795:

  • Beneish M-Score: -2.14
  • GF Value™: NT$389.59 vs. price of NT$193.50 (50.3% below fair value)
  • GF Score™: 78/100 with 5 warning signs

No single metric tells the full story. See the TPE:1795 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lotus Pharmaceutical Co Business Description

Address Song Ren Road, No. 277, 17th Floor, Xin Yi District, Taipei, TWN, 11046
Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. Along with its subsidiaries, it is engaged in the research and development, manufacturing, and sales of generic and branded pharmaceutical products, as well as consulting services. Its product portfolio comprises biosimilars, generic medicines, branded medicines, and various therapies in its research and development pipeline. The Group offers a differentiated portfolio of pharmaceuticals spanning several therapeutic areas, including oncology and immunology, CNS, women's health, primary care and lifestyle, and nephrology, among others. Geographically, it generates maximum revenue from the United States, and the rest from Taiwan, South Korea, Singapore, and other countries.
78GF Score

Get the complete analysis for TPE:1795

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$193.50
Price
NT$389.59
GF Value